1887
2 - Second Qatar Allergy Conference
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Introduction: Subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) are used for the treatment of primary immunodeficiency (PIDD). SCIG is as effective as IVIG in preventing infections.1 However, SCIG has advantages over IVIG as it causes fewer systemic reactions and can be infused at home by the patient leading to improved quality of life.2

Methods: We retrospectively analyzed adult patients with PIDD who received SCIG in an Adult Allergy Clinic in Qatar. Patients who received IVIG before SCIG and are naïve to IgG replacement were included. We compared Serum IgG levels, the number of antibiotic courses received, and the number of hospital admissions one year before and one year after starting SCIG. SF36 score was used to compare health-related quality of life scores before SCIG and after one year of SCIG.

Results: Twenty patients were included in the study, of which 17 were on prior IVIG replacement, and three were naive to replacement. SCIG replacement resulted in the maintenance of serum IgG levels in those who received IVIG prior. SCIG resulted in a statistically significant reduction in the number of antibiotics prescribed and hospitalization in the naïve subgroup but no substantial change in the prior IVIG group. 6/20 patients developed side effects like injection site pain, swelling, and headache. No patients developed significant systemic side effects. 10/20 patients discontinued the SCIG therapy, four patients due to side effects, and others due to noncompliance and financial reasons. SF36 Score was compared for the five patients in IVIG prior group and showed no significant improvement in individual score but improvement in the overall score (p=0.003)

Conclusions: In our experience, SCIG therapy effectively prevents recurrent infection in PIDD patients, and patients did not experience any significant systemic side effects. There is a substantial improvement in the quality of life. However, compliance continues to be a problem.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2023.sqac.3
2023-04-27
2024-06-24
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2023/2/qmj.2023.sqac.3.html?itemId=/content/journals/10.5339/qmj.2023.sqac.3&mimeType=html&fmt=ahah

References

  1. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases Ochs HD, Gupta S, Subcutaneous IgG Study Group. J Clin Immunol. 2006; 26:(3):265 DOI: 10.1007/s10875-006-9021-7
    [Google Scholar]
  2. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Ann Gardulf 1 PMID: 17402794 DOI: 10.2165/00063030-200721020-00005
    [Google Scholar]
/content/journals/10.5339/qmj.2023.sqac.3
Loading
/content/journals/10.5339/qmj.2023.sqac.3
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error